Hill Holliday Health launches inside its Boston-based parent agency

Hill Holliday Health launches with executive creative director David Leonardi and managing director Scott Rabschnuk at the helm. (Business Wire)

Boston ad agency Hill Holliday has been doing pharma and healthcare work for years. But not many people seemed to know about it. So last week, the agency created a health-specific branded agency within itself with the launch of Hill Holliday Health.

The agency made a conscious decision years ago to not brand as a healthcare agency in order to stand out with its consumer approach in the busy healthcare marketing arena, managing director Scott Rabschnuk explained. But more recently, Hill Holliday discovered that, especially when it came to recruiting health marketing talent, people would say they “didn’t even know you guys did healthcare."

RELATED: FCB Health launches stand-alone agency for pharma and healthcare branding

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

“We realized we weren’t on the radar, so we were having a hard time attracting talent and we probably weren’t getting our fair share of at-bats with clients,” he said. “We can still be that consumer-oriented healthcare organization and our work speaks for itself, but we need to brand ourselves and give ourselves an identity so that both prospective clients as well as great industry talent, knows we’re on the map.”

The 120-person workforce of Hill Holliday Health will continue its work for pharma clients such as Novartis and Johnson & Johnson’s Janssen for brands Xarelto and Invokana, as well as pitch for new business and look to hire more healthcare talent.

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.